Local view for "http://purl.org/linkedpolitics/eu/plenary/2004-09-14-Speech-2-140"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20040914.10.2-140"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:translated text |
"Madam President, Mr Czarnenecki, it is a pleasure for me to be able to contribute to the debate here in this Parliament. The fact that the previous debate on Belarus and this one on genetically-modified organisms have coincided is testament to the fact that you are doing a good job of defending your views, Mr Czarnenecki, and that is your job.
I would like to say to you that the current Community legislation, which is the result of the negotiations between this Parliament and the Council on a proposal from the Commission, finally granted the Commission the power to authorise a genetically-modified organism by means of a legislative procedure know as the comitology procedure. This procedure – as the honourable Member is aware – is used in many areas of Community legislation, and is provided for in the current legislation, and allows the Member States of the Union to play an important role and the European Parliament to participate.
This procedure does not authorise the Commission to act against a majority in the Council. Nevertheless, when there is no sufficient majority in the Council – when there is a majority, but not a sufficient one – in favour of or against the proposed measure, the Commission can and must act.
In authorising this NK 603 line, therefore, the Commission will simply be fulfilling its obligation to apply Community legislation, and I would like to point out that the companies legitimately trust that their applications will be dealt with fairly and objectively, in accordance with the Community legislation in force approved by this Parliament and by the Council.
With regard to the new varieties, they will all be analysed in a fair manner, with the two essential objectives: their traceability and the verification that they are harmless to health and to the environment.
To this end, each new variety proposed will have to be analysed in the context of an individualised approval. There will be no generic approvals."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples